Art Never Melts: Huion's Prime Day 2025 Cool Creative Deals
Huion is offering discounts of up to 30% off, including a range of creative equipment for everyone, from beginners to professionals. Let's take a quick look!
Stay Cool, Create Bold
Kamvas Pro 19 and Kamvas Pro 24 ( 4K ) are designed for studio-grade workflows, making them ideal for artists working on large-scale and detailed projects.
Kamvas Pro 19 is the mainstay of the Gen 3 family, featuring an 18.4-inch 4K screen, Canvas Glass, ΔE<1.5 color accuracy, PenTech 4.0, and touch function. Now it's priced at only $899 - an absolute investment worth making!
For artists who crave a bigger screen, Kamvas Pro 24 ( 4K ) is the perfect option. With a 23.8-inch 4K display, it offers more space for your creative projects.
If you're an artist running a small business or an art school student, Kamvas 13 (Gen 3) is the go-to choice. As another member of the Gen 3 family, it also offers flagship-grade features, and it's available for just $202 (with a stand) during Prime Day!
Beach-Ready Creativity
For those who need to create on the go - whether commuting or capturing a beach moment, here are two picks:
Huion Note: The digital smart notebook magically transfers your handwritten content or sketch to your phone in real-time, allowing you to export and share your notes in PDF format for brainstorming and discussions. During Prime Day, it's available for just $101 .
Kamvas Slate 13: Perfect for multimedia entertainment such as reading, gaming, binge-watching and drawing. This Android tablet is easy to use, making it suitable for both parents and children. During Prime Day, you can grab it for $359 with a 20% discount.
Start Your Artistic Journey
If you're new to digital painting and unsure which pen tablet to choose, don't worry! Inspiroy H1060P is beginner-friendly, featuring a 10 x 6.25-inch size and 12 programmable keys. With 8192 levels of pressure sensitivity, it delivers natural and smooth strokes. Now priced at just $42 , it offers great value for online learning and marking assignments.
Where to Buy?
Discounts may vary depending on your country or region. To find more details about the products, please visit your local store!
Americas
US (Amazon): https://amzn.to/3SNdPkB
CA (Amazon): https://amzn.to/3slcA4i
MX (Amazon): https://bit.ly/3QFArDY
BR (Amazon): https://amzn.to/3WExS7l
Europe
UK (Amazon): https://amzn.to/3Cfhl1f
DE (Amazon): https://amzn.to/3LwaJi8
FR (Amazon): https://amzn.to/3UsmH09
IT (Amazon): https://amzn.to/3MDsnlF
ES (Amazon): https://amzn.to/40EDUqL
NL (Amazon): https://amzn.to/3SsuYQ9
Asia & Pacific
JP (Amazon): https://amzn.to/3U8KIsQ
IN (Amazon): https://amzn.to/3rcnHYO
AE (Amazon) : https://amzn.to/3fmxYPE
SA (Amazon): https://bit.ly/3rchBHV
AU (Amazon): https://amzn.to/3FPDOTI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Analysts Offer Insights on Technology Companies: Intuit (INTU) and Roper Technologies (ROP)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Intuit (INTU – Research Report) and Roper Technologies (ROP – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Intuit (INTU) In a report released today, Brent Thill from Jefferies maintained a Buy rating on Intuit, with a price target of $850.00. The company's shares closed last Tuesday at $701.03, close to its 52-week high of $714.78. According to Thill is a 5-star analyst with an average return of 13.2% and a 64.2% success rate. Thill covers the Technology sector, focusing on stocks such as International Business Machines, Palantir Technologies, and Procore Technologies. ;'> Intuit has an analyst consensus of Strong Buy, with a price target consensus of $843.86, implying a 18.0% upside from current levels. In a report issued on August 18, Barclays also maintained a Buy rating on the stock with a $815.00 price target. Roper Technologies (ROP) Citi analyst George Kurosawa initiated coverage with a Buy rating on Roper Technologies yesterday and set a price target of $626.00. The company's shares closed last Tuesday at $532.59. According to Kurosawa is ranked #9177 out of 9989 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Roper Technologies with a $640.23 average price target, implying a 20.3% upside from current levels. In a report issued on August 12, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $616.00 price target.
Globe and Mail
21 minutes ago
- Globe and Mail
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies. 'I am delighted to welcome Martin Steegmaier to Molecular Partners, where his extensive expertise in oncology, business and leadership will provide further impetus to our efforts to deliver unique cancer therapies,' said Patrick Amstutz, Ph.D., CEO of Molecular Partners. 'Martin's experience will be invaluable in leading the research organization and as we continue to innovate and advance our pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation.' Martin Steegmaier joins Molecular Partners from SOTIO Biotech, a clinical-stage company developing immunotherapies for cancer, where he was CSO and lead the development of a broad pipeline of oncology programs. Martin has extensive experience from senior roles at major biotech and pharma companies, including as Head of Research at MorphoSys, focusing on the development of antibody-based therapeutics in immuno-oncology and hematology-oncology. He previously held various positions in pharma partnering and oncology disease areas at Roche, becoming Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center in Munich, and at Boehringer Ingelheim in oncology drug discovery. Martin graduated from the Northern Arizona University and holds a Ph.D. in biochemistry from the University of Basel and an MBA from the Edinburgh Business School. Martin Steegmaier, Ph.D., said: 'I'm pleased to join the exceptional team at Molecular Partners and to contribute to pioneering the cutting-edge DARPin therapeutics. I have built up considerable experience in oncology over my career, including developing large molecules at Roche and other organizations, which is directly relevant to the advancement of Molecular Partners' exciting DARPin platforms and pipeline. I am looking forward to working with the team and to driving forward the next generation of DARPin therapeutics for patients with high unmet need.' About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact: Seth Lewis, SVP Investor Relations & Strategy Concord, Massachusetts, U.S. Tel: +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Globe and Mail
an hour ago
- Globe and Mail
Source Capital Funding, Inc. Named Among California's Best Hard Money Lenders
Source Capital Funding, Inc., a leading direct private money lender, is proud to be recognized among the best hard money lenders in California, prominently supporting real estate investors with fast, transparent, and flexible business-purpose financing. Founded with a commitment to streamlined, asset-based lending, Source Capital has funded over $550 million in loans secured by real estate since 2007. The company leverages more than 40 years of combined experience to support investors, real estate professionals, businesses, and those in need of funding in high-demand regions like Los Angeles, San Francisco, and San Diego. Today, it's among the most trusted partners for real estate professionals seeking rapid, no-nonsense loan solutions. Over the past few years, Source Capital has maintained: Approvals in as little as 24 hours, funding within days, no appraisal fees. First position loans: up to 65% LTV, interest rates between 8.99-11.99%. Second position loans: up to 50% CLTV, one-year terms at 11.99-13.99%. Pricing structured by loan-to-value and loan term, with no prepayment penalties. Origination fees aligned with loan risk; underwriting fee of $3,975-$4,975. Exclusive business-purpose loans, excluding personal-use projects, ground-up construction, hospitality, special-use, and rural-only transactions. 'Our goal is simple: provide our clients the capital they need quickly through our streamlined process,' said Sacha Ferrandi, Founding Partner at Source Capital Funding, Inc. 'With clear terms and responsive funding, we underpin our clients' success with integrity and urgency.' Why Source Capital Stands Out: About Source Capital Funding, Inc. Source Capital Funding, Inc. is a direct private lender specializing in hard money loans for real estate investors in California, Arizona, Colorado, Minnesota, and Texas. With a sharp focus on asset based, business-purpose transactions, Source Capital continues to deliver financially sound, efficient lending to help its clients get the financing they need quickly and at fair terms. Visit or call (888) 235-7191 to learn more. Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. Media Contact Company Name: Source Capital Funding, Inc. Contact Person: Sacha Ferrandi Email: Send Email Country: United States Website:
